CATALOGO DEI PRODOTTI DELLA RICERCA
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishUnconjugated, toxin-conjugated or radiolabeled antibodies (Ab) recognizing tumor-associated antigens have proven beneficial for solid and hematolymphoid neoplasms. A suitable antigen for targeted therapy could be Prostate Stem Cell Antigen (PSCA), a cell surface-antigen expressed at low levels in normal prostate and over expressed in prostate, pancreatic and bladder carcinoma. Anti PSCA mAb was obtained by hybridoma technology and a recombinant version in single chain format (scFv) was generated by cloning the variable heavy (VH) and light chain (VL) sequences in the expression vector pHEN-2. mAb and scFv ability to recognize native PSCA was assessed by flow cytometry on SW780 (PSCA+) cells. The mAb demonstrated a good specificity and affinity, whereas the scFv showed a lower staining compared to whole mAb. The affinity/avidity of scFv was partially recovered making it divalent by cross-linking myc Tag by pre-incubation with anti myc-Ab. mAb was also able to recognize the glycosylated PSCA on prostate and pancreatic neoplastic tissue lysates by Western Blot. The antibody internalization assay demonstrated that the Ab-PSCA complex was internalized. This property was exploited for intracellular delivering of cytotoxic agents. The sequence coding for the Pseudomonas aeruginosa exotoxin A mutant PE40 was cloned at the 3′-end of the scFv yielding an anti-PSCA recombinant immunotoxin. Analysis of cytotoxic activity and specificity of scFv-PE40 are on-going
| Titolo: | Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma | |
| Autori: | ||
| Data di pubblicazione: | 2009 | |
| Abstract: | Unconjugated, toxin-conjugated or radiolabeled antibodies (Ab) recognizing tumor-associated antigens have proven beneficial for solid and hematolymphoid neoplasms. A suitable antigen for targeted therapy could be Prostate Stem Cell Antigen (PSCA), a cell surface-antigen expressed at low levels in normal prostate and over expressed in prostate, pancreatic and bladder carcinoma. Anti PSCA mAb was obtained by hybridoma technology and a recombinant version in single chain format (scFv) was generated by cloning the variable heavy (VH) and light chain (VL) sequences in the expression vector pHEN-2. mAb and scFv ability to recognize native PSCA was assessed by flow cytometry on SW780 (PSCA+) cells. The mAb demonstrated a good specificity and affinity, whereas the scFv showed a lower staining compared to whole mAb. The affinity/avidity of scFv was partially recovered making it divalent by cross-linking myc Tag by pre-incubation with anti myc-Ab. mAb was also able to recognize the glycosylated PSCA on prostate and pancreatic neoplastic tissue lysates by Western Blot. The antibody internalization assay demonstrated that the Ab-PSCA complex was internalized. This property was exploited for intracellular delivering of cytotoxic agents. The sequence coding for the Pseudomonas aeruginosa exotoxin A mutant PE40 was cloned at the 3′-end of the scFv yielding an anti-PSCA recombinant immunotoxin. Analysis of cytotoxic activity and specificity of scFv-PE40 are on-going | |
| Handle: | http://hdl.handle.net/11562/340889 | |
| Appare nelle tipologie: | 04.01 Contributo in atti di convegno |
File in questo prodotto:
Copyright © 2021